Eric Dobmeier - 11 Aug 2023 Form 4 Insider Report for CHINOOK THERAPEUTICS, INC.

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
11 Aug 2023, 16:07:10 UTC
Prior SEC filing
02 Jun 2023
Next SEC filing
14 Nov 2023
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Kirk Schumacher, Attorney-in-Fact

Key filing fact

Eric Dobmeier filed Form 4 for CHINOOK THERAPEUTICS, INC. on 11 Aug 2023.

Key facts

  • This page summarizes Eric Dobmeier's Form 4 filing for CHINOOK THERAPEUTICS, INC..
  • 12 reported transactions and 11 derivative rows are listed below.
  • Accepted by SEC: 11 Aug 2023, 16:07.

Change

  • Previous filing in this sequence was filed on 02 Jun 2023.
  • Current net transaction value: -$49,603,161.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KDNY transaction

Common Stock

Disposed to Issuer

Transaction value
Shares
-301,138
Change %
-100%
Price
Shares after
0
Date
11 Aug 2023
Ownership
Direct
Footnotes
F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KDNY transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
$14,010,645
Shares
-353,358
Change %
-100%
Price
$39.65
Shares after
0
Date
11 Aug 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
353,358
Exercise price
$0.3500
Footnotes
F2
KDNY transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
$12,410,507
Shares
-313,555
Change %
-100%
Price
$39.58
Shares after
0
Date
11 Aug 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
313,555
Exercise price
$0.4200
Footnotes
F3
KDNY transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
$6,853,654
Shares
-271,647
Change %
-100%
Price
$25.23
Shares after
0
Date
11 Aug 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
271,647
Exercise price
$14.77
Footnotes
F4
KDNY transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
$4,439,996
Shares
-178,600
Change %
-100%
Price
$24.86
Shares after
0
Date
11 Aug 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
178,600
Exercise price
$15.14
Footnotes
F5
KDNY transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
$8,130,000
Shares
-300,000
Change %
-100%
Price
$27.10
Shares after
0
Date
11 Aug 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
300,000
Exercise price
$12.90
Footnotes
F6
KDNY transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
$3,758,360
Shares
-255,150
Change %
-100%
Price
$14.73
Shares after
0
Date
11 Aug 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
255,150
Exercise price
$25.27
Footnotes
F7
KDNY transaction Derivative

Restricted Stock Units

Disposed to Issuer

Transaction value
Shares
-30,797
Change %
-100%
Price
Shares after
0
Date
11 Aug 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
30,797
Exercise price
Footnotes
F8, F9
KDNY transaction Derivative

Restricted Stock Units

Disposed to Issuer

Transaction value
Shares
-20,248
Change %
-100%
Price
Shares after
0
Date
11 Aug 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
20,248
Exercise price
Footnotes
F8, F10
KDNY transaction Derivative

Restricted Stock Units

Disposed to Issuer

Transaction value
Shares
-50,001
Change %
-100%
Price
Shares after
0
Date
11 Aug 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
50,001
Exercise price
Footnotes
F8, F11
KDNY transaction Derivative

Restricted Stock Units

Disposed to Issuer

Transaction value
Shares
-64,050
Change %
-100%
Price
Shares after
0
Date
11 Aug 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
64,050
Exercise price
Footnotes
F8, F12
KDNY transaction Derivative

Restricted Stock Units

Disposed to Issuer

Transaction value
Shares
-11,300
Change %
-100%
Price
Shares after
0
Date
11 Aug 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
11,300
Exercise price
Footnotes
F8, F13
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Eric Dobmeier is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 13 footnotes

Footnote F1

The reported securities were disposed of pursuant to the Merger Agreement (defined in the Remarks below). Upon effectiveness of the Merger (defined in the Remarks below), in exchange for each share of the Issuer's Common Stock, the reporting person received: (i) $40.00 in cash, without interest and less applicable withholding taxes; and (ii) one contractual contingent value right (each, a "CVR"), entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement (the "Contingent Value Rights Agreement") entered into concurrent with completion of the Merger.

Footnote F2

This stock option award, which provided for 25% of the award to vest on April 1, 2020 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.

Footnote F3

This stock option award, which provided for 25% of the award to vest on March 6, 2021 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.

Footnote F4

This stock option award, which provided for 25% of the award to vest on October 6, 2021 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.

Footnote F5

This stock option award, which provided for 25% of the award to vest on February 10, 2022 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.

Footnote F6

This stock option award, which provided for 25% of the award to vest on January 31, 2023 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.

Footnote F7

This stock option award, which provided for 25% of the award to vest on January 31, 2024 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.

Footnote F8

When granted, each restricted stock unit ("RSU") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement.

Footnote F9

When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on October 6, 2021. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR.

Footnote F10

When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on February 10, 2022. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR.

Footnote F11

When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on January 31, 2023. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR.

Footnote F12

When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on January 31, 2024. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR.

Footnote F13

When granted, the RSU award provided for the vesting of restricted stock units for shares of the Issuer's Common Stock contingent upon the achievement of certain performance-based vesting conditions. Pursuant to the Merger Agreement, at the effective time of the Merger, the performance-based RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR.

SEC remarks

The reported securities were disposed of by the reporting person pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 11, 2023, by and among Novartis AG, a company organized under the laws of Switzerland ("Parent"), Cherry Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Parent ("Merger Sub"), and the Issuer, which was previously disclosed by the Issuer on its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on June 12, 2023 (File No. 001-37345). In connection with the closing of the transactions contemplated by the Merger Agreement, on August 11, 2023, Merger Sub merged (the "Merger") with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .